INTRODUCTION
The current standard for clinical practice, established through evidence-based reviews by the American Academy of Sleep Medicine (AASM) is to confirm the diagnosis of obstructive sleep at the patient's home. While no optimal portable monitoring device exists, a device must at least supply sufficiently certain diagnostic measurements and be adaptable for use at home by inexperienced patients. Portable monitoring (PM) has been utilized as an alternative diagnostic test for obstructive sleep apnoea (OSA) based in part on the premise that it is less expensive and quicker to deploy compared to in-laboratory PSG. However, there is a paucity of evidence that shows PM is equivalent to PSG in regards to diagnosis, treatment, and outcomes. In most reported literatures, it was stated that PM can be as accurate as PSG for diagnosis in selected populations candidate for PM. [4] [5] [6] [7] [8] [9] [10] [11] [12] In this study, we compared a portable monitoring device with PSG for the measurement of parameters related to diagnosis of OSAS. The device used a novel computer algorithm based on a combination of oxygen saturation and photoplethysmography via pulse wave analysis to detect both respiratory and non-respiratory sleep disorders. 4, 5, 14, 15 After evaluating all of the patients' reports in the study, appointments were made for the patients for an overnight PSG test at the sleep laboratory. On the day of the laboratory stay, the patients were advised not to sleep during the day, not to consume any caffeinated beverages or food, and not to use alcohol and drugs such as antihistamines, antidepressants, or hypnotics which would affect their sleep patterns. 
METHODS

Study
OSAS-related Definitions
Apnoea: A complete lack of air flow through the mouth and nose for ≥10 s. Hypopnea: Less than or equal to 50% air flow for ≥10 s, along with a 3% decrease in oxygen saturation or development of arousal.
Apnoea-Hypopnea Index (AHI):
The ratio obtained by dividing the total duration of apnoea and hypopnea observed during sleep by the total duration of sleep. Informed consent was obtained from all subjects, and the study was approved by the Sakarya University Faculty of Medicine Ethics Committee.
RESULTS
There were 125 male and 30 female (19.4%) patients. The demographic and clinical features of the patients are summarized in Table-I . When questioned about OSAS major symptoms, 81.9% (127/155) of patients had snoring, and in 54.8% (85/155), this snoring was determined to be habitual. Daytime sleepiness was found in 51.6%(80/155) and witnessed apnea was found in 37.4%(58/155). The demographic and clinical features of the patients are summarized in Table-I. We found differences between meanO 2 and DI, found no differences between AHI and minO 2 upon comparison of SM and PSG measurement methods. MinO 2 level was the same in both methods because there was no timed index value.
AHI, meanO 2 , minO 2 , and desaturation indeks (DI) values' scatter plot (Bland & Altman plots) drawn between the differences and averages (These values were obtained by the methods of SM and PSG) is between ±1.96 SD. Since it is between ±1.96 SD, correlations was seen between two methods.
DISCUSSION
In this study, we compared the SM portable monitoring device with PSG for measurement
Obstructive sleep apnoea Data shown as n (%) and mean ± standard deviation. of parameters related to the diagnosis of OSAS. We found differences in the meanO 2 and DI, but found no difference in the AHI and minO 2 between the two measurement methods. Differences between the methods were not desired. However, the relationship between the methods, showing differences in the measured values, supported our hypothesis. The high level of O 2 saturation in the SM measurements was due to the fact that the patients spent a greater number of hours in the awakened state. AHI, DI, and meanO 2 levels in the SM group were low for the same reason. MinO 2 levels were the same in both methods because there was no timed index value. Therefore, even when a patient slept for a short time, the results were not affected. Nocturnal oximetry may be used as a screening method because it may demonstrate the presence of apnoea or hypopnea, but does not distinguish between central or devices record in the sleep state, and both the AHI and arousals are obstructive disorders. Furthermore, it does not detect events without desaturation. Therefore, the use of nocturnal oximetry as a single diagnostic method is not recommended. None of these four type are commonly Cahit Bilgin et al. underestimated. Various surrogate measures of arousals such as actigraphy have been shown to improve the arousal index and possibly the agreement between OSAS diagnosis and PSG. 5, 6 Any improvement may only be slight and not clinically important, as reported by Masa et al. 7 in case of a type 3 device. In recent years, such devices have been validated for PSG at different sensitivities and specificities, depending on the device or AHI cut off value. 8, 9 The results of these studies have shown that single-channel nasal airflow pressure can be used as a definite alternative diagnostic tool in this population, either at home or in a sleep clinic.
OSAS is more prevalent than asthma, chronic obstructive pulmonary disease (COPD), or diabetes. OSAS must be conducted at different health levels, because OSAS is already a widespread concern for public wellness. Cost analyses are complicated by the variability of the type 4 devices. This analysis has demonstrated cost savings from the use of oximetry, but the considerable loss of diagnostic certainty did not eventually allow for a costeffective approach. 10 A study was conducted on the use of a portable monitoring device (Somnocheck Micro) for the research and diagnosis of obstructive sleep apnoea: comparison with polysomnography. The apnoea/ hypopnoea index (AHI) acquired by manual SC analysis correlated closely with that obtained by PSG (r = 0.98).
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CONCLUSIONS
The results of our study have shown that the SM portable device can be used as an alternative diagnostic tool in this population either at home or in sleep clinic. Grant Support & Financial Disclosures: None.
